Scientists have developed a revolutionary 3D modeling technique using skin cells from human lips, paving the way for more effective treatments for facial injuries and congenital conditions like cleft lip and palate. This groundbreaking research promises to improve surgical outcomes and enhance the quality of life for countless individuals.
MexStemCells, a Mexico City-based leader in regenerative medicine, has partnered with PlacidWay Medical Tourism to broaden the reach of its cutting-edge stem cell therapies. This collaboration will provide patients around the globe with access to innovative treatments for chronic and life-threatening conditions like joint degeneration, kidney failure, multiple sclerosis, and autism.
European Wellness Biomedical Group and Jilin Hanxing Group have announced a strategic partnership to create a state-of-the-art Regenerative Medicine and Health Complex in Sanya, China. This collaboration aims to advance global wellness initiatives by combining Eastern and Western approaches to health and wellness, while also boosting medical tourism in Sabah, Malaysia.
The global cell expansion market is projected to experience significant growth, reaching US$ 40.1 billion by 2034. This expansion is driven by factors such as the increasing prevalence of chronic diseases, advancements in cell culture techniques, and growing investments in regenerative medicine. Artificial intelligence and machine learning are revolutionizing cell expansion processes, while the shift towards decentralized healthcare and point-of-care treatments is driving the development of portable and user-friendly technologies.
CollPlant Biotechnologies and Stratasys are collaborating to develop 3D printed regenerative breast implants using CollPlant’s rhCollagen-based bioinks. The pre-clinical study aims to evaluate the implants’ ability to stimulate natural breast tissue growth and completely degrade over time, offering a potential game-changer in breast reconstruction and augmentation procedures.
Phase Holographic Imaging (PHI), a medical technology company specializing in non-invasive cell imaging, has announced its listing on the OTCQB Venture Market in the US. This move aims to enhance accessibility for US investors and facilitate more transparent trading, supporting PHI’s growth in the regenerative medicine field.
